Provided by Tiger Fintech (Singapore) Pte. Ltd.

Liquidia Technologies Inc

15.12
-0.3200-2.07%
Post-market: 15.120.00000.00%19:56 EDT
Volume:1.06M
Turnover:16.12M
Market Cap:1.28B
PE:-9.35
High:15.62
Open:15.18
Low:15.08
Close:15.44
Loading ...

Company Profile

Company Name:
Liquidia Technologies Inc
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
145
Office Location:
419 Davis Drive,Suite 100,Morrisville,North Carolina,United States
Zip Code:
27560
Fax:
919 328 4402
Introduction:
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Directors

Name
Position
Neal Fowler
Director, Chief Executive Officer
Arthur Kirsch
Independent Director
Joanna Horobin
Independent Director
Katherine Rielly Gauvin
Independent Director
Ralph Snyderman
Independent Director
Raman Singh
Independent Director
Seth Rudnick
Independent Director
Stephen Bloch
Independent Director, Chairperson of the Board

Shareholders

Name
Position
Neal Fowler
Director, Chief Executive Officer
Benjamin Maynor
Senior Vice President, Research and Development
Florina Krawchick
Senior Vice President, Human Resources
Jeri Thomas
Senior Vice President, Commercial
Richard D. Katz
Chief Financial Officer
Robert Roscigno
Senior Vice President, Product Development
Robert Lippe
Chief Operations Officer